Navigation Links
Limbs saved by menstrual blood stem cells
Date:8/18/2008

Cells obtained from menstrual blood, termed 'endometrial regenerative cells' (ERCs) are capable of restoring blood flow in an animal model of advanced peripheral artery disease. A study published today in BioMed Central's open access Journal of Translational Medicine demonstrates that when circulation-blocked mice were treated with ERC injections, circulation and functionality were restored.

Critical limb ischemia, an advanced form of peripheral artery disease, causes approximately 150,000 amputations per year in the US. Currently there are no medical or surgical interventions that are effective in the advanced stages of the disease. ERCs are cells taken from menstrual blood that are capable of forming into at least 9 different tissue types, including heart, liver and lung. Their discovery won the 'Medicine Research Award of the Year' award for BioMed Central's Research Awards in 2007.

Dr. Michael Murphy, a vascular surgeon from Indiana University and lead author of this study has already performed clinical trials with adult stem cells for patients with peripheral artery disease. He stated, "The advantage of ERCs is that they can be used in an 'off the shelf' manner, meaning they can be delivered to the point of care, do not require matching, and are easily injectable without the need for complex equipment."

The experiments were performed as a collaboration between University of Western Ontario, Scripps Research Institute, Indiana University, and several other academic centers. The ERC cell population is currently being developed by the US publicly traded company Medistem Inc, who supported these studies.

"We are proud of assembling such a strong, clinically experienced team to contribute to these studies" said Dr. Thomas Ichim, CEO of Medistem. "Dr. Ewa Carrier and Suman Kambhampati are hematologists who use stem cells on a regular basis, Dr. Angle is a vascular surgeon, who like Dr. Murphy sees CLI on a daily basis, and Dr. Amit Patel has performed numerous cardiac stem cell clinical trials. With such a team that understands not only the science, but also the practical implementation, we feel we are well positioned to translate this discovery into a practical therapy in the near future".


'/>"/>
Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-707-94804
BioMed Central
Source:Eurekalert

Related biology technology :

1. Physicists saved from drowning in complexities of wetting theory
2. Stem Cells From Menstrual Blood Show Therapeutic Potential
3. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
4. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
5. New CO-oximetry Module for the ABL80 FLEX Blood Gas Analyzer
6. Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
7. GeneNews launches worlds first blood test for colorectal cancer screening
8. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
9. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
10. InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring
11. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... TORONTO , Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... operational results for the fourth quarter and fiscal year ended September ... , , ... Toronto -based life sciences and diagnostics company that develops and ... Commercial Highlights Achieved revenues of $1.4 million ...
(Date:12/6/2016)... Fort Collins, Colorado (PRWEB) , ... December 06, ... ... developer of dynamic aqueous plasma technology platforms, announced today that the company has ... five-year Master Research and Development Agreement (MRDA) with the CSU Office of the ...
(Date:12/6/2016)... Dec. 6, 2016  SRI International has been ... from the National Institutes of Health,s National Institute ... of AIDS (NIAID-DAIDS) to support the manufacturing and ... (PreP) agents. Under the seven-year contract, SRI will ... services for candidate HIV-prevention products that emerge from ...
(Date:12/5/2016)... ... 2016 , ... This composition patent, U.S. Patent No. 9,499,637, ... composition claims are not limited to any particular process to make or use ... fibers, graphene, and other materials. A continuation application, U.S. Patent App. No. ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a privately ... products for the objective detection of concussion and other ... has successfully completed a meeting with the U.S. Food ... blood test Pre-Submission Package. During the meeting company representatives ... as a precursor to commencement of a planned pilot ...
Breaking Biology News(10 mins):